Arkema's Stock Jumps 4.26% Midday After UBS Upgrade

New Analyst Recommendation Boosts Arkema

Today's session is highlighted by the publication of a new analyst recommendation on Arkema. UBS has increased its price target from 61 to 62 euros, while issuing a buy rating on the specialty chemicals company. At the current price of 54.48 euros, this target implies a potential revaluation of about 13.8%. This positive signal accompanies a rebound movement after a challenging week for the stock, which showed a decline of 6.16% over the past seven days. Over a year, the performance remains significantly negative at -34.21%, reflecting the headwinds that have weighed on the chemical sector. However, over three months, the stock retains a gain of 7.87%, indicating an attempt at stabilization that began earlier in the year. The next milestone for the group will be the publication of its first-quarter 2026 results, scheduled for May 6.

Despite Rebound, Arkema's Technical Situation Remains Fragile

Despite the surge observed this Tuesday, Arkema's technical situation remains fragile. The Relative Strength Index (RSI), which measures overbought or oversold conditions of a stock, is at 24, a particularly low level indicating a pronounced oversold zone. This threshold reflects the magnitude of the recent correction and can be interpreted as a signal of a possible technical rebound, of which today's session might be an initial manifestation. Moreover, the stock is trading below its main moving averages: the MM50, at 55.49 euros, and the MM200, at 56.78 euros, serve as intermediate resistances. The major resistance is located at 65.45 euros. The identified support at 50.70 euros has so far contained the selling pressure. This rebound occurs in a context of easing on European exchanges, with the CAC 40 advancing 2.16% in the session while the DAX gains 2.22%. The VIX, a barometer of volatility on American markets, remains high at 29.49 points, reflecting a still significant level of tension on global markets.